⌘K

Login Start Free

Home/Filings/4/0001127602-24-001603

4//SEC Filing

Eisele Jeffrey 4

Accession 0001127602-24-001603

CIK 0001492422other

View on SEC.gov Company Profile

Filed

Jan 17, 7:00 PM ET

Accepted

Jan 18, 4:55 PM ET

Size

4.5 KB

Accession

0001127602-24-001603

Insider Transaction Report

Form 4

Period: 2024-01-17

Apellis Pharmaceuticals, Inc.APLS

Chief Development Officer

Transactions

Sale
Common Stock
2024-01-17$65.58/sh−5,207$341,475→ 67,443 total

Footnotes (1)

[F1]This is a scheduled sale from an established 10b5-1 plan.

Documents

1 file

4
form4.xmlPrimary
PRIMARY DOCUMENT

Issuer

Apellis Pharmaceuticals, Inc.

CIK 0001492422

Entity typeother

Related Parties

1

filerCIK 0001827326

Filing Metadata

Form type: 4
Filed: Jan 17, 7:00 PM ET
Accepted: Jan 18, 4:55 PM ET
Size: 4.5 KB

View on SEC.gov